HomeStrategyA $435 Million Bet on ‘Reversing Aging’ Strategy A $435 Million Bet on ‘Reversing Aging’ Strategy June 7, 2026 0 341 FacebookXPinterestWhatsApp Biotech startup NewLimit secures a major funding round after claiming a ‘breakthrough discovery’ of a prototype medicine that rewinds cellular aging in the liver. FacebookXPinterestWhatsApp Cody Previous articleDell sharpens data protection strategy as AI reshapes cyber resilienceNext articleLayoffs don’t have to feel inhumane RELATED ARTICLES Strategy CoreWeave’s Revenue Hits Record $3.7 Billion As CEO Defends Debt-Laden Model Strategy The Great Wealth Transfer Is About More Than Money. Here’s What’s Being Overlooked. Strategy A viral TikTok trend is turning ordinary photos into something unexpectedly emotional Strategy How ‘key person risk’ derails companies—and poses problems for Nvidia amid the Jensen Huang scandal Must Read Industrial automation startup Path Robotics raises $300M in funding Tech What we learned about the hyperscalers from earnings season Tech Reverse mortgage leaders on alleviating sales and referral pain points Real Estate Higharc, ECI launch MarkSystems integration for big builders Real Estate CoreWeave’s Revenue Hits Record $3.7 Billion As CEO Defends Debt-Laden Model Strategy